Investing in a company that's on the verge of being able to sell a drug for the first time is as close as it gets to a slam dunk in the world of biotech. With the clinical trial process in the rearview mirror, a lot of the risks associated with development are in the past, leaving "only" the risks of competing profitably.
Such is the situation of Cara Therapeutics (NASDAQ: CARA), which is developing a drug called Korsuva to treat pruritus. You've probably experienced pruritus (at least to a small degree) before, because it's the sensation of itchiness. But, with pathologies like chronic kidney disease (CKD), and chronic liver disease (CLD), itching isn't something that's trivial to relieve with a quick scratch for many patients. It's frequently a severe and pervasive problem that dramatically reduces a patient's quality of life, which is where Korsuva could help.
Image source: Getty Images.
Source Fool.com